BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) investors concerning the ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) ...
LOS ANGELES, Nov. 13, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) have ...
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) on behalf of investors concerning the ...
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting ...
Artificial intelligence-powered marketing platform company Jasper Inc. today announced the launch of Jasper Studio, a new service that gives marketers the ability to design and deploy AI apps and ...
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results